Kezar Q3 net loss $17.8M; positive lupus nephritis data and FDA IND clearance

Kezar Life Sciences, Inc.

2022-Q3 EPS reported -$0.76

Net loss $17.8M ($0.25/share) vs $14.5M in Q3 2021; operating expenses rose to $18.9M.
Cash $290.4M at Sept 30, up from $208.4M at Dec 31, 2021, driven by ATM proceeds.
MISSION Phase 2 lupus nephritis: ORR 64.7% at week 25, 88.2% at week 37; CRR 35.3% then 41.2%.
FDA cleared IND for zetomipzomib in autoimmune hepatitis; PORTOLA Phase 2a trial to start.
Preclinical KZR-540, an oral PD-1 expression blocker, presented at SITC on Nov 11.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Kezar Life Sciences Reports Third Quarter 2022 Financial Results

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.